IntelliCell BioSciences (New York, NY), developer of a technology that processes stromal vascular fraction (SVF) cells containing a high concentration of adipose—or fat—stem cells within 30 minutes, had its technology tested using a flow cytometry method by Millipore (Billerica, MA), a division of Merck, with positive results. This could lead to better treatment of arthritis, orthopedic injuries, congestive heart failure, gum recession, and wound healing, along with several other ailments.
IntelliCell believes that it is currently the only company that does not use enzymes in processing adipose tissue, and actually counts and checks the adipose stem cells they manufacture.
Millipore performed an antibody flow cytometry study of IntelliCell's technology, which showed that the company's manufactured cells yielded an average of 10 times the number of SVF cells containing adult adipose stem cells, from less fat than that which IntelliCell believes is used by its competition using enzymes in their process. The study also showed that IntelliCell's cells contain all of the viable cells that are manufactured by competing technologies.
These adipose stem cells have similar potential to embryonic stem cells in their pluripotency, in vast number, from a source that involves no moral or ethical issues, as well as no chemical additives required for digestion of the tissue.
In aesthetics, using autologous adipose stem cells has become widely accepted in Europe and Asia. But since the U.S. FDA published its laws on autologous stem cells in mid-2009, the field has expanded rapidly.
Posted by Lee Mather
Follow OptoIQ on your iPhone; download the free app here.
Subscribe now to BioOptics World magazine; it's free!